Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis
A Phase III, Double Blind, Randomized, Placebo-Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF)
Status: Enrolling
Updated:  12/31/1969
21st Century Oncology - Fort Apache
mi
from
Las Vegas, NV
Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis
A Phase III, Double Blind, Randomized, Placebo-Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF)
Status: Enrolling
Updated: 12/31/1969
21st Century Oncology - Fort Apache
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis
A Phase III, Double Blind, Randomized, Placebo-Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF)
Status: Enrolling
Updated:  12/31/1969
21st Century Oncology - Vegas Tenaya
mi
from
Las Vegas, NV
Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis
A Phase III, Double Blind, Randomized, Placebo-Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF)
Status: Enrolling
Updated: 12/31/1969
21st Century Oncology - Vegas Tenaya
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis
A Phase III, Double Blind, Randomized, Placebo-Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF)
Status: Enrolling
Updated:  12/31/1969
21st Century Oncology
mi
from
Las Vegas, NV
Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis
A Phase III, Double Blind, Randomized, Placebo-Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF)
Status: Enrolling
Updated: 12/31/1969
21st Century Oncology
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis
A Phase III, Double Blind, Randomized, Placebo-Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF)
Status: Enrolling
Updated:  12/31/1969
Cancer and Blood Specialists-Shadow
mi
from
Las Vegas, NV
Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis
A Phase III, Double Blind, Randomized, Placebo-Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF)
Status: Enrolling
Updated: 12/31/1969
Cancer and Blood Specialists-Shadow
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis
A Phase III, Double Blind, Randomized, Placebo-Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF)
Status: Enrolling
Updated:  12/31/1969
Cancer and Blood Specialists-Tenaya
mi
from
Las Vegas, NV
Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis
A Phase III, Double Blind, Randomized, Placebo-Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF)
Status: Enrolling
Updated: 12/31/1969
Cancer and Blood Specialists-Tenaya
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis
A Phase III, Double Blind, Randomized, Placebo-Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF)
Status: Enrolling
Updated:  12/31/1969
Cancer Therapy and Integrative Medicine
mi
from
Las Vegas, NV
Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis
A Phase III, Double Blind, Randomized, Placebo-Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF)
Status: Enrolling
Updated: 12/31/1969
Cancer Therapy and Integrative Medicine
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis
A Phase III, Double Blind, Randomized, Placebo-Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF)
Status: Enrolling
Updated:  12/31/1969
Comprehensive Cancer Centers of Nevada - Central Valley
mi
from
Las Vegas, NV
Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis
A Phase III, Double Blind, Randomized, Placebo-Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF)
Status: Enrolling
Updated: 12/31/1969
Comprehensive Cancer Centers of Nevada - Central Valley
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis
A Phase III, Double Blind, Randomized, Placebo-Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF)
Status: Enrolling
Updated:  12/31/1969
Comprehensive Cancer Centers of Nevada - Northwest
mi
from
Las Vegas, NV
Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis
A Phase III, Double Blind, Randomized, Placebo-Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF)
Status: Enrolling
Updated: 12/31/1969
Comprehensive Cancer Centers of Nevada - Northwest
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis
A Phase III, Double Blind, Randomized, Placebo-Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF)
Status: Enrolling
Updated:  12/31/1969
Comprehensive Cancer Centers of Nevada-Summerlin
mi
from
Las Vegas, NV
Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis
A Phase III, Double Blind, Randomized, Placebo-Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF)
Status: Enrolling
Updated: 12/31/1969
Comprehensive Cancer Centers of Nevada-Summerlin
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis
A Phase III, Double Blind, Randomized, Placebo-Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF)
Status: Enrolling
Updated:  12/31/1969
Comprehensive Cancer Centers of Nevada
mi
from
Las Vegas, NV
Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis
A Phase III, Double Blind, Randomized, Placebo-Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF)
Status: Enrolling
Updated: 12/31/1969
Comprehensive Cancer Centers of Nevada
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis
A Phase III, Double Blind, Randomized, Placebo-Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF)
Status: Enrolling
Updated:  12/31/1969
HealthCare Partners Medical Group Oncology/Hematology-Centennial Hills
mi
from
Las Vegas, NV
Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis
A Phase III, Double Blind, Randomized, Placebo-Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF)
Status: Enrolling
Updated: 12/31/1969
HealthCare Partners Medical Group Oncology/Hematology-Centennial Hills
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis
A Phase III, Double Blind, Randomized, Placebo-Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF)
Status: Enrolling
Updated:  12/31/1969
HealthCare Partners Medical Group Oncology/Hematology-Maryland Parkway
mi
from
Las Vegas, NV
Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis
A Phase III, Double Blind, Randomized, Placebo-Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF)
Status: Enrolling
Updated: 12/31/1969
HealthCare Partners Medical Group Oncology/Hematology-Maryland Parkway
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis
A Phase III, Double Blind, Randomized, Placebo-Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF)
Status: Enrolling
Updated:  12/31/1969
HealthCare Partners Medical Group Oncology/Hematology-San Martin
mi
from
Las Vegas, NV
Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis
A Phase III, Double Blind, Randomized, Placebo-Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF)
Status: Enrolling
Updated: 12/31/1969
HealthCare Partners Medical Group Oncology/Hematology-San Martin
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis
A Phase III, Double Blind, Randomized, Placebo-Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF)
Status: Enrolling
Updated:  12/31/1969
HealthCare Partners Medical Group Oncology/Hematology-Tenaya
mi
from
Las Vegas, NV
Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis
A Phase III, Double Blind, Randomized, Placebo-Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF)
Status: Enrolling
Updated: 12/31/1969
HealthCare Partners Medical Group Oncology/Hematology-Tenaya
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis
A Phase III, Double Blind, Randomized, Placebo-Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF)
Status: Enrolling
Updated:  12/31/1969
Las Vegas Cancer Center-Medical Center
mi
from
Las Vegas, NV
Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis
A Phase III, Double Blind, Randomized, Placebo-Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF)
Status: Enrolling
Updated: 12/31/1969
Las Vegas Cancer Center-Medical Center
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis
A Phase III, Double Blind, Randomized, Placebo-Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF)
Status: Enrolling
Updated:  12/31/1969
Nevada Cancer Research Foundation CCOP
mi
from
Las Vegas, NV
Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis
A Phase III, Double Blind, Randomized, Placebo-Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF)
Status: Enrolling
Updated: 12/31/1969
Nevada Cancer Research Foundation CCOP
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis
A Phase III, Double Blind, Randomized, Placebo-Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF)
Status: Enrolling
Updated:  12/31/1969
Radiation Oncology Centers of Nevada Central
mi
from
Las Vegas, NV
Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis
A Phase III, Double Blind, Randomized, Placebo-Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF)
Status: Enrolling
Updated: 12/31/1969
Radiation Oncology Centers of Nevada Central
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis
A Phase III, Double Blind, Randomized, Placebo-Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF)
Status: Enrolling
Updated:  12/31/1969
Radiation Oncology Centers of Nevada Southeast
mi
from
Las Vegas, NV
Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis
A Phase III, Double Blind, Randomized, Placebo-Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF)
Status: Enrolling
Updated: 12/31/1969
Radiation Oncology Centers of Nevada Southeast
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis
A Phase III, Double Blind, Randomized, Placebo-Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF)
Status: Enrolling
Updated:  12/31/1969
Summerlin Hospital Medical Center
mi
from
Las Vegas, NV
Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis
A Phase III, Double Blind, Randomized, Placebo-Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF)
Status: Enrolling
Updated: 12/31/1969
Summerlin Hospital Medical Center
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis
A Phase III, Double Blind, Randomized, Placebo-Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF)
Status: Enrolling
Updated:  12/31/1969
Saint Mary's Regional Medical Center
mi
from
Reno, NV
Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis
A Phase III, Double Blind, Randomized, Placebo-Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF)
Status: Enrolling
Updated: 12/31/1969
Saint Mary's Regional Medical Center
mi
from
Reno, NV
Click here to add this to my saved trials
Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis
A Phase III, Double Blind, Randomized, Placebo-Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF)
Status: Enrolling
Updated:  12/31/1969
Duke Univ Med Ctr
mi
from
Durham, NC
Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis
A Phase III, Double Blind, Randomized, Placebo-Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF)
Status: Enrolling
Updated: 12/31/1969
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis
A Phase III, Double Blind, Randomized, Placebo-Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF)
Status: Enrolling
Updated:  12/31/1969
Miami Valley Hospital South
mi
from
Centerville, OH
Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis
A Phase III, Double Blind, Randomized, Placebo-Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF)
Status: Enrolling
Updated: 12/31/1969
Miami Valley Hospital South
mi
from
Centerville, OH
Click here to add this to my saved trials
Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis
A Phase III, Double Blind, Randomized, Placebo-Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF)
Status: Enrolling
Updated:  12/31/1969
Oncology Hematology Care Inc - Anderson
mi
from
Cincinnati, OH
Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis
A Phase III, Double Blind, Randomized, Placebo-Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF)
Status: Enrolling
Updated: 12/31/1969
Oncology Hematology Care Inc - Anderson
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis
A Phase III, Double Blind, Randomized, Placebo-Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF)
Status: Enrolling
Updated:  12/31/1969
Oncology Hematology Care Inc - Kenwood
mi
from
Cincinnati, OH
Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis
A Phase III, Double Blind, Randomized, Placebo-Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF)
Status: Enrolling
Updated: 12/31/1969
Oncology Hematology Care Inc - Kenwood
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis
A Phase III, Double Blind, Randomized, Placebo-Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF)
Status: Enrolling
Updated:  12/31/1969
Oncology and Hematology Care Inc - Blue Ash
mi
from
Cincinnati, OH
Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis
A Phase III, Double Blind, Randomized, Placebo-Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF)
Status: Enrolling
Updated: 12/31/1969
Oncology and Hematology Care Inc - Blue Ash
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis
A Phase III, Double Blind, Randomized, Placebo-Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF)
Status: Enrolling
Updated:  12/31/1969
Oncology Hematology Care Inc-Eden Park
mi
from
Cincinnati, OH
Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis
A Phase III, Double Blind, Randomized, Placebo-Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF)
Status: Enrolling
Updated: 12/31/1969
Oncology Hematology Care Inc-Eden Park
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis
A Phase III, Double Blind, Randomized, Placebo-Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF)
Status: Enrolling
Updated:  12/31/1969
Oncology Hematology Care Inc-Mercy West
mi
from
Cincinnati, OH
Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis
A Phase III, Double Blind, Randomized, Placebo-Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF)
Status: Enrolling
Updated: 12/31/1969
Oncology Hematology Care Inc-Mercy West
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis
A Phase III, Double Blind, Randomized, Placebo-Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF)
Status: Enrolling
Updated:  12/31/1969
Dayton NCI Community Oncology Research Program
mi
from
Dayton, OH
Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis
A Phase III, Double Blind, Randomized, Placebo-Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF)
Status: Enrolling
Updated: 12/31/1969
Dayton NCI Community Oncology Research Program
mi
from
Dayton, OH
Click here to add this to my saved trials
Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis
A Phase III, Double Blind, Randomized, Placebo-Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF)
Status: Enrolling
Updated:  12/31/1969
Good Samaritan Hospital - Dayton
mi
from
Dayton, OH
Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis
A Phase III, Double Blind, Randomized, Placebo-Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF)
Status: Enrolling
Updated: 12/31/1969
Good Samaritan Hospital - Dayton
mi
from
Dayton, OH
Click here to add this to my saved trials
Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis
A Phase III, Double Blind, Randomized, Placebo-Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF)
Status: Enrolling
Updated:  12/31/1969
Miami Valley Hospital
mi
from
Dayton, OH
Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis
A Phase III, Double Blind, Randomized, Placebo-Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF)
Status: Enrolling
Updated: 12/31/1969
Miami Valley Hospital
mi
from
Dayton, OH
Click here to add this to my saved trials
Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis
A Phase III, Double Blind, Randomized, Placebo-Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF)
Status: Enrolling
Updated:  12/31/1969
Oncology Hematology Care Inc-Healthplex
mi
from
Fairfield, OH
Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis
A Phase III, Double Blind, Randomized, Placebo-Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF)
Status: Enrolling
Updated: 12/31/1969
Oncology Hematology Care Inc-Healthplex
mi
from
Fairfield, OH
Click here to add this to my saved trials
Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis
A Phase III, Double Blind, Randomized, Placebo-Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF)
Status: Enrolling
Updated:  12/31/1969
Blanchard Valley Hospital
mi
from
Findlay, OH
Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis
A Phase III, Double Blind, Randomized, Placebo-Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF)
Status: Enrolling
Updated: 12/31/1969
Blanchard Valley Hospital
mi
from
Findlay, OH
Click here to add this to my saved trials
Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis
A Phase III, Double Blind, Randomized, Placebo-Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF)
Status: Enrolling
Updated:  12/31/1969
Atrium Medical Center - Middletown Regional Hospital
mi
from
Franklin, OH
Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis
A Phase III, Double Blind, Randomized, Placebo-Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF)
Status: Enrolling
Updated: 12/31/1969
Atrium Medical Center - Middletown Regional Hospital
mi
from
Franklin, OH
Click here to add this to my saved trials
Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis
A Phase III, Double Blind, Randomized, Placebo-Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF)
Status: Enrolling
Updated:  12/31/1969
Wayne Hospital
mi
from
Greenville, OH
Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis
A Phase III, Double Blind, Randomized, Placebo-Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF)
Status: Enrolling
Updated: 12/31/1969
Wayne Hospital
mi
from
Greenville, OH
Click here to add this to my saved trials
Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis
A Phase III, Double Blind, Randomized, Placebo-Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF)
Status: Enrolling
Updated:  12/31/1969
Kettering Medical Center
mi
from
Kettering, OH
Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis
A Phase III, Double Blind, Randomized, Placebo-Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF)
Status: Enrolling
Updated: 12/31/1969
Kettering Medical Center
mi
from
Kettering, OH
Click here to add this to my saved trials
Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis
A Phase III, Double Blind, Randomized, Placebo-Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF)
Status: Enrolling
Updated:  12/31/1969
Springfield Regional Cancer Center
mi
from
Springfield, OH
Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis
A Phase III, Double Blind, Randomized, Placebo-Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF)
Status: Enrolling
Updated: 12/31/1969
Springfield Regional Cancer Center
mi
from
Springfield, OH
Click here to add this to my saved trials
Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis
A Phase III, Double Blind, Randomized, Placebo-Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF)
Status: Enrolling
Updated:  12/31/1969
Springfield Regional Medical Center
mi
from
Springfield, OH
Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis
A Phase III, Double Blind, Randomized, Placebo-Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF)
Status: Enrolling
Updated: 12/31/1969
Springfield Regional Medical Center
mi
from
Springfield, OH
Click here to add this to my saved trials
Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis
A Phase III, Double Blind, Randomized, Placebo-Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF)
Status: Enrolling
Updated:  12/31/1969
Upper Valley Medical Center
mi
from
Troy, OH
Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis
A Phase III, Double Blind, Randomized, Placebo-Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF)
Status: Enrolling
Updated: 12/31/1969
Upper Valley Medical Center
mi
from
Troy, OH
Click here to add this to my saved trials
Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis
A Phase III, Double Blind, Randomized, Placebo-Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF)
Status: Enrolling
Updated:  12/31/1969
University of Oklahoma Health Sciences Center
mi
from
Oklahoma City, OK
Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis
A Phase III, Double Blind, Randomized, Placebo-Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF)
Status: Enrolling
Updated: 12/31/1969
University of Oklahoma Health Sciences Center
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis
A Phase III, Double Blind, Randomized, Placebo-Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF)
Status: Enrolling
Updated:  12/31/1969
Christiana Care Health System-Concord Health Center
mi
from
Chadds Ford, PA
Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis
A Phase III, Double Blind, Randomized, Placebo-Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF)
Status: Enrolling
Updated: 12/31/1969
Christiana Care Health System-Concord Health Center
mi
from
Chadds Ford, PA
Click here to add this to my saved trials
Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis
A Phase III, Double Blind, Randomized, Placebo-Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF)
Status: Enrolling
Updated:  12/31/1969
Huntsman Cancer Institute at University of Utah
mi
from
Salt Lake City, UT
Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis
A Phase III, Double Blind, Randomized, Placebo-Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF)
Status: Enrolling
Updated: 12/31/1969
Huntsman Cancer Institute at University of Utah
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis
A Phase III, Double Blind, Randomized, Placebo-Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF)
Status: Enrolling
Updated:  12/31/1969
Froedtert and the Medical College of Wisconsin
mi
from
Milwaukee, WI
Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis
A Phase III, Double Blind, Randomized, Placebo-Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF)
Status: Enrolling
Updated: 12/31/1969
Froedtert and the Medical College of Wisconsin
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis
A Phase III, Double Blind, Randomized, Placebo-Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF)
Status: Enrolling
Updated:  12/31/1969
Cancer Center of Western Wisconsin
mi
from
New Richmond, WI
Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis
A Phase III, Double Blind, Randomized, Placebo-Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF)
Status: Enrolling
Updated: 12/31/1969
Cancer Center of Western Wisconsin
mi
from
New Richmond, WI
Click here to add this to my saved trials
Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis
A Phase III, Double Blind, Randomized, Placebo-Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF)
Status: Enrolling
Updated:  12/31/1969
Northwestern University
mi
from
Chicago, IL
Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis
A Phase III, Double Blind, Randomized, Placebo-Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF)
Status: Enrolling
Updated: 12/31/1969
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis
A Phase III, Double Blind, Randomized, Placebo-Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF)
Status: Enrolling
Updated:  12/31/1969
Minnesota Oncology Hematology PA-Maplewood
mi
from
Maplewood, MN
Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis
A Phase III, Double Blind, Randomized, Placebo-Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF)
Status: Enrolling
Updated: 12/31/1969
Minnesota Oncology Hematology PA-Maplewood
mi
from
Maplewood, MN
Click here to add this to my saved trials
Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis
A Phase III, Double Blind, Randomized, Placebo-Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF)
Status: Enrolling
Updated:  12/31/1969
Hennepin County Medical Center
mi
from
Minneapolis, MN
Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis
A Phase III, Double Blind, Randomized, Placebo-Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF)
Status: Enrolling
Updated: 12/31/1969
Hennepin County Medical Center
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis
A Phase III, Double Blind, Randomized, Placebo-Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF)
Status: Enrolling
Updated:  12/31/1969
The Mayo Clinic
mi
from
Rochester, MN
Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis
A Phase III, Double Blind, Randomized, Placebo-Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF)
Status: Enrolling
Updated: 12/31/1969
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis
A Phase III, Double Blind, Randomized, Placebo-Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF)
Status: Enrolling
Updated:  12/31/1969
Minnesota Oncology and Hematology PA-Woodbury
mi
from
Woodbury, MN
Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis
A Phase III, Double Blind, Randomized, Placebo-Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF)
Status: Enrolling
Updated: 12/31/1969
Minnesota Oncology and Hematology PA-Woodbury
mi
from
Woodbury, MN
Click here to add this to my saved trials
Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis
A Phase III, Double Blind, Randomized, Placebo-Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF)
Status: Enrolling
Updated:  12/31/1969
Alegent Health Immanuel Medical Center
mi
from
Omaha, NE
Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis
A Phase III, Double Blind, Randomized, Placebo-Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF)
Status: Enrolling
Updated: 12/31/1969
Alegent Health Immanuel Medical Center
mi
from
Omaha, NE
Click here to add this to my saved trials
Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis
A Phase III, Double Blind, Randomized, Placebo-Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF)
Status: Enrolling
Updated:  12/31/1969
Columbia University Herbert Irving Cancer Center
mi
from
New York, NY
Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis
A Phase III, Double Blind, Randomized, Placebo-Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF)
Status: Enrolling
Updated: 12/31/1969
Columbia University Herbert Irving Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials